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The Importance of Screening for Medullary Thyroid Carcinoma in
Families of Patients with MEN 2
A. Frilling,* P.E. Goretzki,* L . Bastian,* and H.D. Roeher*

Family .screening for medullary thyroid cancer (MTC) is important for detecting members of multiple
endocrine neoplasia type 2 (MEN 2) families who may be gene carriers but show no chnical evidence
ofthe disease. Most members of our MEN 2 families are screened yearly by measuring basal and
pentagastrin-stimulated calcitonin (CT) levels. A 15-year-old first-degree relative ofan affected
member of the D-kindred showed a normal basal and an elevated stimulated CT level. Clinical
examination, ultrasonography, and scintigraphy were normal. Thyroidectomy and bilateral neck
dissection revealed a multicentric MTC with no lymph node involvement. In the O-kindred we delected
elevated basal andior stimulated CT levels in three asymptomatic first-degree relatives. At surgery we
found a small multicentric MTC in one family member, C-ceU hyperplasia in another member, and
bilateral lymph node metastases in one member who had been previously thyroidectomized. Basal and
stimulated CT estimations in MEN 2 family members provide an effective method for detecting MTC in
early, treatable stages. (Henry Ford Hosp MedJ 1989;37:122-3)

edullary thyroid carcinoma (MTC) occurs in about 25% of
patients in the hereditary form (1,2), Prospective screening for hereditary MTC began in 1969 when Melvin et at (1,3)
performed studies on the J-kindred. Clinical penetrance of the
mulriple endocrine neoplasia type 2 (MEN 2) gene has been
shown to be incomplete in that less than 100% of gene carriers
win show clinical symptoms (4,5). Measurement of basal and
stimulated calcitonin (CT) and carcinoembryonic anrigen
(CEA) in semm allows detection of affected subjects (6-10). Because surgery is the only effective therapeutic procedure and
only patients in occult tumor stage can be treated curatively,
family screening for MTC is of great importance. This study
presents the results of screening in two MEN 2 families.

M

Case Reports
Case 1
MTC, pheochromocytoma, and Hirschsprung's disease have been
known to occur in the D-kindred since 1979, This 16-year-old male had
a segmental colon resection at age I year and a subtotal colectomy for
Hirschspmng's disease at age 3 years. The patient's mother had a thyroidectomy in 1983 for a MTC, and screening for MTC was pertomied
yearly on the patient thereafter The mother's brothen two sisters, and
the son of one sister have had MTC and pheochromocytomas. Two sons
of the other affected sister have had MTC and Hirschspmng's disease.
Basal and pentagastrin-stimulated CT levels and CEA were within the
normal range (CT < IOO pg/mL, CEA < 5 ng/mL) until 1986 when CT
had increased to 186 pg/mL basally and to 944 pg/mL after pentagastrin
stimulation (0,5 fig/kg body weight). The CEA was 13,5 ng/mL (Figure). Physical examination, ultrasonography, and scintigraphy were
normal. The patient underwent total thyroidectomy and bilateral modified neck dissection, and histologic study showed a multifocular MTC
without metastases to the cervical nodes. Postoperatively the basal and
stimulated CT levels have been normal (Figure).
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Case 2
This 26-year-old female is a member of the O-kindred with MEN
2A. In 1977 she had atrial septal defect surgery. She has had recurrent
kidney stones since 1981. Parathyroid hormone (PTH) and calcium
blood levels were elevated to 1.05 ng/mL and 6.4 mmol/mL, respectively (normal range less than 0.55 ng/mL and 4.9 mmol/mL, respectively). Attempts to localize a parathyroid adenoma by computed tomography were unsuccessful, and the patient had neck exploration and
removal of a parathyroid adenoma in 1986. Postoperatively PTH and
calcium decreased to normal. In 1987 the patient developed palpitations
with tachycardia but her blood pressure was normal. Her plasma epinephrine level was elevated to 416 ng/L (normal 90 to 130 ng/L) and
urinary excretion of vanillylmandelic acid was 66 mg/day (normal less
than 7.5 mg/day). The basal CT level was 54 pmol/L (normal less than
100 pmol/mL) and increased to a peak value of 581 pmol/L after pentagastrin. The CEA was within the normal range. Computed tomography confirmed bilateral adrenal masses. Bilateral pheochromocytomas
were removed first and thyroidectomy and bilateral modified neck dissection were performed later The histologic examination confirmed the
presence of a small MTC with no lymph node metastases. Thc patient
has been screened yeariy and no evidence for tumor recurrence has
been found.
Case 3
This 27-year-old female member of the O-kindred was screened annually for MTC and pheochromocytoma. In 1987 the basal CT level was
within the normal range but the pentagastrin-stimulated CT level was
elevated to a peak value of 865 pmol/L. The CEA level was also elevated
(7.26 ng/mL). Clinical examination and ultrasonography ofthe thyroid
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showed no abnormalities. On thyroidectomy and bilateral neck dissection C-cell hyperplasia was found with no metastases to the lymph
nodes. Postoperatively stimulated CT levels decreased to normal.
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Case 4
This 48-year-old female was the index case of the O-kindred, having
had a left adrenalectomy for pheochromocytoma in 1983. Thyroid enlargement was observed first in 1976. In 1987 a cold thyroid nodule was
detected by scintigraphy. The basal CT level was elevated to 2,240
pmol/L. The patient underwent thyroidectomy, and multicentric MTC
with lymph node metastases were found. Two months later the patient
had bilateral neck dissection which revealed two small metastases. In
1988 basal and stimulated CT were within the normal range but had increased in 1989 to 130 pmol/L and 2,100 pmol/L, respectively, even
though clinical examination, ultrasonography, computed tomography,
and " ' I meta-iodo-benzylguanidine showed no evidence of any tumor
recurrences.

Discussion
MTC is a rare thyroid neoplasm characterized by the CT-secrering t u m o r and the p o s s i b i l i t y o f f a m i l i a l occunence. Surgery is a curative therapeutic procedure (1,11-13) onty when the
disease is still i n the occult stage. C T assay provides a diagnostic
tool for the detecfion o f M T C in clinically unapparent cases (3).
By frequent screening in our M E N 2 kindreds (one with patients
w i t h H i r s c h s p r u n g ' s disease as w e t t as M T C and p h e o chromocytomas), we have been able to diagnose the M T C i n
three famity members in preclinical stages.
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